Medtronic and Abbott, two of the world’s largest healthcare technology companies, have launched a groundbreaking partnership focused on improving care for patients with type 1 and type 2 diabetes. Typically seen as rivals in the competitive diabetes care landscape, the two companies are now collaborating on a new continuous glucose monitor (CGM) that will use Abbott’s FreeStyle Libre sensors and work exclusively with Medtronic’s smart insulin delivery systems and software.
The partnership encompasses both automated insulin delivery (AID) and multiple daily injection (MDI) systems. The final products, designed to enhance diabetes management, will be sold exclusively by Medtronic. This collaboration aims to improve access to CGM devices globally, providing an essential resource for patients with both type 1 and type 2 diabetes.
Financial terms of the deal have not been disclosed.
“Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and Smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world,” said Que Dallara, executive vice president and president of Medtronic’s diabetes division, in a statement.
“This partnership pairs two global leaders in glucose sensing technology and insulin delivery,” added Jared Watkin, executive vice president of Abbott’s diabetes care business. “Abbott’s CGM technology has set the standard for accurate, accessible, easy-to-use, and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic’s advanced insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.”
The integration of Abbott’s advanced CGM technology with Medtronic’s insulin delivery systems signifies a major advancement in diabetes care. This partnership highlights the ongoing efforts of these leading companies to innovate and improve the quality of life for people managing diabetes.
Related topics:
Breakthrough T1D Walk Returns to Morgantown for Type 1 Diabetes Research
NovaLead’s Repurposed Drug for Diabetic Foot Ulcer Receives CDSCO Approval
